Gene Therapy for Dry AMD Using AAV to Improve Durability & Compliance
1:50 pm - Wednesday 25th March 2026
- Complement Inhibitors clinically validated for treatment of dry AMD
- AAV vectors can potentially transform treatment from monthly injections to a single long-lasting intervention
- Intravitreal delivery using novel AAV capsid
